1. X
  2. bioAffinity Technologies
Log inSign up
bioAffinity Technologies
596 posts
bioAffinity Technologies profile banner
user avatar

bioAffinity Technologies

@bioAffinity
Joined June 2020
112
Following
289
Followers
RepliesRepliesMediaMedia
  • user avatar
    bioAffinity Technologies
    @bioAffinity
    Aug 7
    Physicians often rely on multiple sources of clinical information to evaluate pulmonary nodules for cancer. CyPath Lung provides real-time diagnostic insight that complements imaging and other clinical findings for earlier detection of malignancy. cypathlung.com $BIAF
    00:00
  • user avatar
    bioAffinity Technologies
    @bioAffinity
    Aug 7
    bioAffinity Technologies reported second quarter 2026 financial results and continued strong commercial momentum for CyPath® Lung. CyPath® Lung test volume increased 216% year over year as physician adoption continued to grow. bit.ly/4hVySkc $BIAF
  • user avatar
    bioAffinity Technologies
    @bioAffinity
    Aug 5
    Patients want answers they can understand. CyPath Lung provides additional diagnostic information to help physicians assess malignancy risk. This physician knows that a negative CyPath Lung test result eases a patient’s anxiety and provides reassurance about next steps. $BIAF
    00:00
  • user avatar
    bioAffinity Technologies
    @bioAffinity
    Aug 4
    Managing indeterminate pulmonary nodules takes more than one perspective. Hear an interventional pulmonologist, thoracic surgeon and medical oncologist discuss where #CyPathLung fits into patient evaluation. 🎙️Listen: bit.ly/4w4koSA $BIAF #lungcancer
  • user avatar
    bioAffinity Technologies
    @bioAffinity
    Aug 2
    Our Veterans' health is a top priority. So proud to support NAVREF as we bring CyPath Lung to improve care for the men and women who served our country
    navref.regfox.com
    2026 NAVREF Conference

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.